Abstract 3869: The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)
Raffaella Soldi(Banner Health), Sunil Sharma(Translational Genomics Research Institute), Mohan R. Kaadige(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), Rhonda Lewis(Translational Genomics Research Institute), William P.D. Hendricks(Translational Genomics Research Institute), Hariprasad Vankayalapati(University of Utah), Alexis Weston(Translational Genomics Research Institute)
Cited by 3
Related Papers
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47
MondoA-Mlx Transcriptional Activity Is Limited by mTOR-MondoA Interaction
|Molecular and Cellular Biology|2014|41
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
|Oncotarget|2018|27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma
|Molecular Cancer Therapeutics|2018|24